dkNET community events and announcements in February, 2022

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.

dkNET News

• Join dkNET Upcoming Webinars: (1) The Stimulating Peripheral Activity To Relieve Conditions (SPARC): Advancing Bioelectronic Medicine Through Open Science, presented by Dr. Maryann Martone, will be held on Friday, February 11, 2022, 11 am-12 pm PT. (2) dkNET New Investigator Pilot Program in Bioinformatics Awardee Webinar “Uncovering Novel Mediators and Mechanism of Leptin Action,” presented by Dr. Alan Rupp on February 25, 2022, 11 am-12 pm PT. Learn more: https://dknet.org/about/webinar. 

• Funding Opportunity: dkNET New Investigator Pilot Program in Bioinformatics 

Are you an early-stage/new investigator who wants to develop and apply computational methods to support diabetes, endocrinology or metabolic disease research? Submit your application for this RFP by February 28, 2022.

• 2022 dkNET Summer of Data Student Program To support researchers with the use of online resources, the 6-week dkNET Summer of Data Student Program provides students an opportunity to utilize the dkNET tools and resources in a research project. Students will learn the best practices to enhance rigor and reproducibility, as well as the basics of good data management via FAIR (Findable, Accessible, Interoperable, Reusable) data principles. dkNET will award a $1,000 scholarship to a limited number of high school, undergraduate or graduate (Masters or PhD) students who are working in an NIDDK-related research lab during summer 2022. Awards will be determined by a competitive selection process. Application due date: April 18, 2022.

• dkNET Co-PI Dr. Maryann Martone Presents at State of the Science 2022 Hosted by the(sugar)science dkNET Co-PI Dr. Maryann Martone will present at the upcoming State of the Science 2022: Cutting Edge Technologies /In Silico Solutions for T1D Research on January 27, 2022 at 8 am PST. Join us for this informative conversation and learn new tools! Learn more: https://dknet.org/about/blog/2390

• Congratulations to dkNET Co-PI Dr. Maryann Martone & colleagues! The misidentified cell lines study and Rigor the Transparency Index, developed by Dr. Martone and the FDI (FAIR Data Informatics) lab members, are mentioned in the newly published article “Misidentified biomedical resources: Journal guidelines are not a quick fix” (Hepkema WM et al. via International Journal of Cancer). Check out other recently published reproducibility-related articles to learn how to make cancer biology research more reproducible, the reasons reproducibility reform fails, reproducibility in microscopy, & more! Reproducibility Articles: https://dknet.org/about/blog/2392

• New Resources added to dkNET
• AI Researchers Portal (RRID:SCR_021887) is a portal for connecting Artificial Intelligence researchers to Federal resources that can support their AI work from grant funding and datasets to computing and testbeds.
• endoR (RRID:SCR_021916) is a software R package to interpret fitted tree ensemble models. It is used to extract and visualize how predictive variables contribute to tree ensemble model accuracy.
• CSpritz (RRID:SCR_021884) is a web tool for prediction of intrinsic protein disorder segments with annotation for homology, secondary structure and linear motifs.

Events in February 2022

Feb. 02, 2022

Sphingolipid Biology Webinar "Regulation of Ceramide Synthase by Protein-Protein Interaction"

Join the webinar on 02 Feb, 15:30 – 16:00 WET (7:30 - 8:00AM PST), led by Can Senkal. 

More Information: https://www.sphingolipidbiology.com/registrations

Feb. 02, 2022 

Sphingolipid Biology Webinar "S1P controls endothelial sphingolipid homeostasis via ORMDL"

Join the webinar on 02 Feb, 16:00 – 16:30 WET (8:00 - 8:30AM PST), led by Linda Sasset. 

More Information: https://www.sphingolipidbiology.com/registrations

Feb. 02, 2022 

EMBL-EBI Webinar: "MetaboLights: the home for metabolomics experiments and derived information"

MetaboLights is a database for metabolomics experiments and derived information. The database is cross-species, cross-technique and covers metabolite structures and their reference spectra as well as their biological roles, locations and concentrations, and experimental data from metabolic experiments. It is the recommended metabolomics data repository for several leading journals. This webinar will introduce metabolomics data and the MetaboLights resource, including how to submit, access and search relevant data.

The webinar will be presented by Thomas Payne on February 2, 2022 at 15:30 -16:30 GMT (7:30-8:30AM PST)

More Information: https://www.ebi.ac.uk/training/events/metabolights-home-metabolomics-experiments-and-derived-information/

Feb. 04, 2022 

DRTC Friday Seminar Series

DRTC Friday Seminar Series: "TBD" virtual webinar on Friday, February 4, 2022 at 12:00pm CST (10:00am PST)

Speaker: Renata Pereira Alambert, PhD, University of Iowa

More Information: https://www.vumc.org/vdrc/drtc-friday-seminar-series

Feb. 06-09, 2022 

Keystone Symposia: Adipose Tissue and Metabolic Health

Like the obesity and Type 2 epidemic, our understanding of adipocytes and adipose tissue biology continues to expand. Substantial research advances have led to new insights into the contributions of adipose tissue to normal physiology and obesity-related complications, which places adipocyte biology at the epicenter of a global pandemic of metabolic diseases. Our proposed Keystone Symposia conference “Adipose Tissue and Metabolic Health” will consider the locations and functions of different adipose tissue depots, as well as recent studies that use stable isotopies to provide insight into how formation and turnover of adipocyte contributes to metabolic diseases. The secretory capacities of adipose tissue will be covered in several different sessions including “Influences of Adipose Tissue Immune Cells” and “New Adipose Tissue Products-Exosomes and Lipid Containing Vesicles”.

InPerson Location: Keystone Resort, Keystone, CO, USA 

Meeting is available as a Livestream and to view On Demand.

Conference Dates: February 6-9, 2022

Abstract Deadline: November 10 2021

Location:  Keystone Resort, 100 Dercum Square, Keystone, CO 80435, USA

More Information: https://www.keystonesymposia.org/KS/Online/Events/2022Q2/Adipose-Tissue-Metabolic-Health.aspx?EventKey=2022Q2

Feb. 09, 2022 

DRC Virtual Seminar Series: “Metabolic regulation of insulin secretion in health and disease”

The DRC Virtual Seminar Series is hosting its next webinar “Metabolic regulation of insulin secretion in health and disease” on February 9, 2022, 11:00 AM PST| 12:00 MST| 1:00 PM CST | 2:00 PM EST

Speaker: Frances Ashcroft, DBE, FRS, FMedSci

More Information: https://diabetes-virtual-seminar.org/

Feb. 10, 2022 

the(sugar)science The State of Science II: "Exploring Non Mouse Models for studying T1D"

the(sugar)science is hosting The State of Science 2022 T1D Series: "Exploring Non Mouse Models for studying T1D: islet on a chip, organoids, how to best emulate the human islet phenotype" 

The State of Science II is holding this virtual discussion on Thursday, February 10, 2022 at 8-9 am PST // 11-12 noon EST // 4-5 pm GMT

Anchors: Bridget Wagner PhD (MIT), Susan Bonner-Weir PhD (Harvard/Joslin), Teresa Mastraaci PhD (IU), Gopika Nair PhD CEO (EndoCrine Bio)

More Information: https://thesugarscience.org/state-of-the-science-2022/

Feb. 11, 2022 

DRTC Friday Seminar Series

DRTC Friday Seminar Series: "TBD" virtual webinar on Friday, February 11, 2022 at 12:00pm CST (10:00am PST)

Speaker: Alp Ikizler, MD, Vanderbilt University

More Information: https://www.vumc.org/vdrc/drtc-friday-seminar-series

Feb. 11, 2022 

NIH Data Sharing and Reuse Seminar: "Improving Deposition Quality, FAIRness, and Impact of Metabolomics"

The NIH Data Sharing and Reuse Seminar: "Improving Deposition Quality, FAIRness, and Impact of Metabolomics" is being presented by Dr. Hunter Moseley. Dr. Mosely plans to discuss the richness of open data resources in biology and how they can support machine learning approaches and be enriched by such methods. He’ll also discuss how we might think about data sharing to maximize reuse and the value of our public investment.

Join the webinar on Feb. 11, 2022 at 12 p.m. ET (9a.m. PT).

More Information: https://datascience.nih.gov/news/february-data-sharing-and-reuse-seminar-hunter-moseley

Feb. 11, 2022 

dkNET Webinar: The Stimulating Peripheral Activity To Relieve Conditions (SPARC): Advancing Bioelectronic Medicine Through Open Science

Join dkNET Webinar on Friday, Feb. 11, 2022, 11 am - 12 pm PST

The Stimulating Peripheral Activity to Relieve Conditions (SPARC) program is supported by the NIH Common Fund to provide a scientific and technological foundation for future bioelectronic medicine devices and protocols.The goal of the SPARC program is to identify neural targets and accelerate the development of therapeutic devices that modulate electrical activity in the vagus and other nerves to help treat diseases and conditions, such as hypertension and gastrointestinal disorders, by precisely adjusting organ function. The overall vision for the SPARC Portal is to accelerate autonomic neuroscience research and device development by providing access to digital resources that can be shared, cited, visualized, computed, and used for virtual experimentation. Come join us to learn about this useful resource! 

Presenter: Dr. Maryann Martone, Professor Emerita, Department of Neurosciences, University of California San Diego

More Information: https://dknet.org/about/blog/2397

Feb. 15, 2022 

LIPIDMAPS Webinar: "Uncovering complexity of natural epilipidomes"

Maria Fedorova studied Biochemistry at Saint-Petersburg State University, Russia and obtained her PhD at Faculty of Chemistry and Mineralogy, Leipzig University, Germany. Now she is a group leader at the Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, at the University of Leipzig. Her research is focused on development and optimization of chromatography and mass spectrometry methods for analysis of lipids and their modified forms. Dr Fedorova group works on implementation of high throughput LC-MS methods in discovery lipidomics targeting in-depth identification and quantification of human lipidome in variety of tissues.   

Presented by: Dr Maria Fedorova 

Webinar will be streamed live on February 15th, 2022, 9am PST

More Information: https://www.lipidmaps.org/resources/webinars/19

Feb. 22, 2022 

Registration Deadline: NIDDK Workshop: Designing Interventions that Address Structural Racism to Reduce Kidney Health Disparities

Substantial racial and ethnic disparities exist in health outcomes among patients with kidney disease, and structural racism is widely recognized to be a fundamental determinant. Structural racism is defined as macrolevel systems, social forces, institutions, ideologies, and processes that interact with one another to generate and perpetuate inequities among racial and ethnic minority populations. For marginalized racial and ethnic groups, this leads to greater exposure to adverse social determinants and risks (e.g., residential segregation, housing insecurity, food insecurity, inadequate health care, financial resource deprivation) that negatively affect individuals’ risk of chronic kidney disease (CKD) and its progression and contributes to inequitable care and outcomes across the spectrum of CKD. Interventions that dismantle or address the effects of structural racism are essential to achieve health equity for patients with kidney disease.

Registration Deadline: February 22, 2022

Workshop Dates: February 24-25, 2022

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/designing-interventions-address-structural-racism-reduce-kidney-health-disparities

Feb. 24, 2022 

the(sugar)science The State of Science II: "Clinical Trials in T1D"

the(sugar)science is hosting The State of Science 2022 T1D Series: "Clinical Trials in T1D: integrating technology into T1D trials. Strategies for next steps: AI analytics and bioinformatics. Making sense of a sea of data: best practices and ways forward" 

The State of Science II is holding this virtual discussion on Thursday, February 24, 2022 at 8-9 am PST // 11-12 noon EST // 4-5 pm GMT

Anchors: Linda DiMeglio MD (IU), Bridget Wagner PhD (MIT), Marissa Hilliard PhD (Baylor School of Medicine), Marina Basina MD (Stanford)

More Information: https://thesugarscience.org/state-of-the-science-2022/

Feb. 24-25, 2022 

NIDDK Workshop: Designing Interventions that Address Structural Racism to Reduce Kidney Health Disparities

Substantial racial and ethnic disparities exist in health outcomes among patients with kidney disease, and structural racism is widely recognized to be a fundamental determinant. Structural racism is defined as macrolevel systems, social forces, institutions, ideologies, and processes that interact with one another to generate and perpetuate inequities among racial and ethnic minority populations. For marginalized racial and ethnic groups, this leads to greater exposure to adverse social determinants and risks (e.g., residential segregation, housing insecurity, food insecurity, inadequate health care, financial resource deprivation) that negatively affect individuals’ risk of chronic kidney disease (CKD) and its progression and contributes to inequitable care and outcomes across the spectrum of CKD. Interventions that dismantle or address the effects of structural racism are essential to achieve health equity for patients with kidney disease.

Registration Deadline: February 22, 2022

Workshop Dates: February 24-25, 2022

More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/designing-interventions-address-structural-racism-reduce-kidney-health-disparities

Feb. 25, 2022 

dkNET Webinar: Uncovering Novel Mediators and Mechanism of Leptin Action

Join dkNET Webinar on Friday, Feb. 25, 2022, 11 am - 12 pm PST

Rates of obesity and diabetes continue to rise, impacting the health and wellbeing of millions. Treatment options are limited, in part because of our incomplete understanding of the biology of hunger and energy expenditure. The hormone leptin is produced by adipose tissue and signals the repletion of adipose energy stores to leptin receptor (Lepr)-expressing neurons in the hypothalamus. Leptin- and Lepr-deficient humans and rodents display marked hyperphagia, reduced energy expenditure, and extreme obesity. The crucial cellular targets (i.e., Lepr neurons) and transcriptional mechanisms that mediate these responses remain largely unknown, however. To reveal the cellular architecture of Lepr cells, we performed single nucleus RNA-seq of the hypothalamus in lean and obese rodents and macaques and in enriched mouse Lepr neurons. We identified over a dozen distinct Lepr neuron populations distributed across multiple hypothalamic nuclei, including a novel conserved population of Lepr neurons that is marked by Glp1r expression and which displays strong transcriptional responses to diet-induced obesity. Deleting Lepr from these Lepr/Glp1r cells resulted in excessive food intake and weight gain, revealing the importance of these for the control of energy balance by leptin. In contrast, we found that ventromedial hypothalamic (VMH) Lepr neurons represent a distinct class of VMH neurons that promote energy expenditure. Finally, we showed that leptin signaling during obesity remains intact in a subset of hypothalamic Lepr populations, while other Lepr neurons that play key roles in energy balance exhibited blunted responses. Overall, these studies reveal the neuronal structure of leptin action and highlight cell populations and molecular pathways that represent potential targets for obesity therapy.

Presenter: Alan Rupp, Ph.D. Research Investigator, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan (dkNET New Investigator Pilot Program informatics Awardee)

More Information: https://dknet.org/about/webinar

Funding Opportunities Information and Deadlines in December 2021

Feb. 03, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Clinical Centers (U01 Clinical Trial Not Allowed)

The purpose of this FOA is to create a clinical consortium to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goal of this undertaking will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.

Letter of Intent Deadline: February 03, 2022

Application Deadline: March 03, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-002.html

Feb. 03, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Understanding and Targeting the Pathophysiology of Youth-onset Type 2 Diabetes – Biostatistics Research Center (U01 Clinical Trial Not Allowed)

This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to better understand youth-onset type 2 diabetes. A separate FOA (RFA-DK-21-002) invites Clinical Centers to recruit a cohort of early pubertal youth at risk for developing type 2 diabetes and study them through puberty. The ultimate goals of this consortium will be to 1) develop more precise prediction of which individuals are truly at risk for developing youth-onset T2D and identify determinants of progression from prediabetes to T2D so that, ultimately, targeted prevention approaches can be developed and tested; and 2) increase understanding of the physiologic drivers of youth-onset T2D to guide development of more effective strategies to achieve glycemic control and preserve beta cell function.

Letter of Intent Deadline: February 03, 2022

Application Deadline: March 03, 2022 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-003.html

Feb. 03, 2022 

NIDDK Funding Opportunity Letter of Intent Due: High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the organization of the human pancreatic tissue environment by describing the composition and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and the contribution of adjacent tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC) that is part of the Human Islet Research Network or HIRN (https://hirnetwork.org/). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology, as opposed to exploring the biology specific to any animal models.

Letter of Intent Deadline: February 3, 2022

Application Deadline: March 3, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-017.html

Feb. 05, 2022 

NIH Funding Opportunity Application Due: Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)

This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

Letter of Intent due 30 days prior to application.

Application Deadline(s): February 05, 2022, June 05, 2022, October 05, 2022 (...)

More Information: https://grants.nih.gov/grants/guide/pa-files/pa-21-232.html

Feb. 05, 2022 

NIH Funding Opportunity Application Due: Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)

The Stimulating Hematology Investigation:  New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI).  Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain.  Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.

Application Deadline: February 05, 2022; June 05, 2022; October 05, 2022

More Information: https://grants.nih.gov/grants/guide/pa-files/pas-22-096.html

Feb. 05, 2022 

NIDDK Funding Opportunity Application Due: Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)

The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational, or clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. As such, research topics of interest will change over time to take advantage of emerging opportunities. The research topic area previously supported by the SUITOR program, urinary incontinence, will now transition to neurourology, as described below.

Application Deadline: February 5, 2022; June 5, 2022

More Information: https://grants.nih.gov/grants/guide/pa-files/pas-22-074.html

Feb. 08, 2022

NIDDK Funding Opportunity Letter of Intent Due: Diabetes Research Centers (P30 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2021 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org  (http://www.diabetescenters.org).

Letter of Intent Deadline: February 8, 2022

Application Deadline: March 8, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-029.html

Feb. 08, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative, discovery research studies to better characterize early-life risk factors and elucidate underlying causal mechanisms through which these risk factors contribute to the development of obesity during infancy and early childhood. Studies should aim to understand biological mechanisms that mediate behavioral and/or metabolic risk for obesity development in young children and how risk may be modified by other contributors such as psychosocial, contextual, and/or environmental factors. This FOA encourages multidisciplinary teams of scientists including, but not limited to those with expertise in basic, translational, clinical, and behavioral research.

Letter of Intent Deadline: February 8, 2022

Application Deadline: March 8, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-025.html

Feb. 09, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.

Letter of Intent Due Date: February 9, 2022 and September 7, 2022

Application Due Date: March 9, 2022 and October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-011.html 

Feb. 09, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

Letter of Intent Deadline: February 09, 2022 and September 7, 2022

Application Deadline: March 9, 2022 and October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-012.html

Feb. 15, 2022 

NIDDK Funding Opportunity Application Due: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) Application Due Date

The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

Application Deadline: February 15, 2022; May 15, 2022; November 15, 2022

More Information: https://grants.nih.gov/grants/guide/notice-files/not-ns-20-107.html

Feb. 17, 2022 

NIDDK Funding Opportunity Application Due: Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.  The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission.  DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.  Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.

Letter of Intent Deadline: 30 days prior

Application Deadline: February 17, 2021; June 8, 2023

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-026.html

Feb. 17, 2022 

NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D) to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.

Letter of Intent Deadlines: January 17, 2022; September 07, 2022

Application Deadlines: February 17, 2022; October 7, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-021.html

Feb. 18, 2022 

NIH Funding Opportunity Application Due: Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)

Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources.

Letter of intent deadline: 30 days prior to application

Application deadline: February 18, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-007.html

Feb. 24, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)

The overall goal of the Fostering Research With Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the benign urologic research community. FORWARD Urology Centers will support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising junior investigators and/or researchers new to the field of benign urologic research. It is expected that the Research Project Team will generate data to support one or more follow-on independent grant applications (e.g., R01s). The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Team to help ensure the research aims are met and to aid them in their successful integration into the broader benign urologic research field. To facilitate these goals, the Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program.

Letter of Intent Deadline: February 24, 2022

Application Deadline: March 24, 2022

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-032.html

Feb. 24, 2022 

NIDDK Funding Opportunity Letter of Intent Due: Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed)

This Funding Opportunity Announcement intends to support the creation of an Analysis, Technology, Leadership, Administration and Science (ATLAS) Center that has the overarching goal of building the "go-to" open-access resource for the research community of mouse and human renal and genitourinary development and disease. The ATLAS Center will have scientific and administrative responsibilities including: 1) integrating and visualizing disparate datatypes and organs of the renal and genitourinary tract; 2) developing, adopting, or improving state-of-the-art computational tools and approaches to carry out analyses of multi-modal molecular and imaging data; 3) building interactive 2D/3D atlases and molecular maps with FAIR principles (findable, accessible, interoperable, and reusable) to promote data retrieval, exploration, discovery, and analysis by the community; 4) developing, designing, maintaining, and enhancing an open-access, interactive public data and analysis portal; and 5) coordinating internal and external activities of the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and (Re)Building a Kidney (RBK) consortia, including administration of an opportunity pool to address scientific gaps and opportunities.

Letter of Intent Deadline: February 24, 2022

Application Deadline: March 24, 2022 

More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-034.html

Feb. 28, 2022 

NIDDK IIDP Request for Proposals (RFP) Letter of Intent Due: Affiliated Islet Isolation Centers (IICs)

The purpose of this RFP is to identify and evaluate expert human IICs that can provide the highest quality human isolated islets and related tissues to the Integrated Islet Distribution Program (IIDP) in a dependable, consistent, cost-effective manner. IICs are hereby invited to submit an application in response to this Request for Proposals to become an IIDP IIC. The IIC should be led by an experienced investigator with a solid track record of providing resources and services to the diabetes research community, and should have proficiency in procuring and processing human islets for research use.

Informational Webinar: January 24, 2022 at 11am PST

Letter of Intent Due Date: February 28, 2022

Application Due Date: March 31, 2022

More Information: https://iidp.coh.org/iic_rfp?fbclid=IwAR29OF50c2HYlxJrahwQ-jLWKrEM4VYCaWcTO3rYHCVkJWCKnTD8eKDZV84

Feb. 28, 2022 

dkNET Funding Opportunity Application Due: New Investigator Pilot Program in Bioinformatics

As high throughput technologies become routine for individual laboratories in biomedical research, there is a growing need to develop a workforce that can use and further refine the computational approaches needed to interrogate complex data. This pilot program, through the NIDDK Information Network (dkNET), is designed to encourage new investigators to develop and apply innovative bioinformatics approaches to important research problems in Diabetes, Endocrinology and Metabolic Diseases (DEMD). The dkNET New Investigator Pilot Program is designed to: (i) facilitate the ability of Early Stage and New Investigators with computational and bioinformatics expertise to pursue research questions in DEMD, or (ii) allow Early Stage and New PIs currently pursuing DEMD-related research to explore incorporating computational, mathematical, statistical, and/or bioinformatics approaches into their research projects. dkNET Pilot Award applications should focus on applying computational and/or modeling approaches, whether data-driven, mechanism-driven, or integrated, to compelling research problems in diabetes, endocrinology and related metabolic disorders.

Letter of Intent Deadline: January 28, 2022 [LOI should be submitted before 9 pm PST (12 am EST)]

Application Deadline: February 28, 2022 [application should be submitted before 9 pm PST (12 am EST)]

More Information: https://dknet.org/about/new-investigator-pilot